Alendronate Sodium Tablet
Product Images NDC 68071-3771

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 68071-3771). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (1203dd0c 809a 4409 B948 B5e816b8a63a 01)

Chemical structure diagram of alendronate sodium showing its molecular composition including amino group, carbon chain, phosphate groups, and sodium coordinated with three water molecules (trihydrate).*

FDA Label Image

2 (1203dd0c 809a 4409 B948 B5e816b8a63a 02)

A line graph titled 'Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT (patients with radiographic vertebral fracture at baseline)' shows cumulative incidence percentage on the y-axis versus time in months on the x-axis. It compares two treatments, placebo (dashed line) and alendronate sodium (solid line), indicating lower cumulative incidence with alendronate sodium over 36 months.*

FDA Label Image

3 (1203dd0c 809a 4409 B948 B5e816b8a63a 03)

A bar chart titled ‘Osteoporosis Treatment Studies in Postmenopausal women’ showing the increase in bone mineral density (BMD) relative to placebo after three years of Alendronate Sodium 10 mg/day. The chart compares BMD percent increase at three anatomical sites: Lumbar Spine, Femoral Neck, and Trochanter, with separate bars for U.S. and multinational data sets, including standard error bars.*

FDA Label Image

4 (1203dd0c 809a 4409 B948 B5e816b8a63a 04)

This image contains two line graphs comparing the mean percent change in lumbar spine bone mineral density (BMD) from baseline over 36 months. The left graph is labeled US Study and the right graph is Multinational Study. Both graphs compare Alendronate Sodium 10 mg daily versus placebo in postmenopausal women with osteoporosis, showing an increase in BMD over time for those treated with Alendronate Sodium compared to placebo.*

FDA Label Image

5 (1203dd0c 809a 4409 B948 B5e816b8a63a 05)

Two bar charts titled 'Osteoporosis Prevention Studies in Postmenopausal Women' comparing changes in bone mineral density (BMD) from baseline over 2-year and 3-year studies. Each chart shows BMD percent change plus standard error in the lumbar spine, femoral neck, trochanter, and total body areas, contrasting Alendronate Sodium 5mg/day (white bars) with placebo (gray bars).*

FDA Label Image

6 (1203dd0c 809a 4409 B948 B5e816b8a63a 06)

A bar chart titled 'Studies in Glucocorticoid-Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year' comparing mean percent increase in bone mineral density (BMD) relative to placebo at lumbar spine, femoral neck, and trochanter sites between U.S. and multinational groups, with error bars representing standard error.*

FDA Label Image

7 (1203dd0c 809a 4409 B948 B5e816b8a63a 07)

A line graph depicting the effect on serum alkaline phosphatase over time in months. The graph compares Alendronate Sodium 40 mg/day from multinational and U.S. studies with placebo and Etidronate 400 mg/day in Paget's Disease of Bone, showing mean percent change from baseline with sample sizes indicated.*

FDA Label Image

Pdp (68071 3771 5)

Label for Alendronate Sodium 70 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a package of 15 tablets, prescription only, with warnings to keep out of reach of children. It includes NDC 68071-3771-5 and manufacturing details from Cipla Ltd. Tablets are oral dosage form and storage temperature is noted as 68-77°F.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.